47% effective CureVac coronavirus vaccine project misses target | Serum

47% effective CureVac coronavirus vaccine project misses target |  Serum

CureVac Laboratory, from Germany, announced this Wednesday (16) that its main project of Serum Against Covid-19 Show a 47% effectiveness Against disease cases of any severity, according to a temporary analysis of a large-scale disease

Notice, The lab acknowledged that the CureVac vaccine “does not meet the statistical criteria for success”. However, it has shown good levels of security. The analysis included nearly 40,000 participants in Latin America and Europe.

World Health Organization (Who is the) she has Suggest a minimum efficacy of 50% Covid-19 vaccines to be adopted. This is the case for all immunization devices licensed for emergency use in Brazil and currently in force in the country: Coronavac, AstraZeneca e Pfizer/BioNTech.

According to study officials, most cases of Covid-19 seen in volunteers who received two doses of the potential vaccine (not a placebo) were caused by Worrying variants of SARS-CoV-2 coronavirus.

“This variable-rich environment demonstrates the importance of developing a new generation of vaccines, as new types of virus continue to emerge,” warns Franz Werner Haas, CEO of CureVac.

Also, according to a statement, CureVac will continue future research with pharmaceutical company GSK in search of a second-generation vaccine, which will be included in vaccine schedules against Covid next year.

Learn how this technique works in the video below

The Pfizer Covid vaccine uses a technology called messenger RNA;  See how it works

The Pfizer Covid vaccine uses a technology called messenger RNA; See how it works

You May Also Like

About the Author: Camelia Kirk

"Friendly zombie guru. Avid pop culture scholar. Freelance travel geek. Wannabe troublemaker. Coffee specialist."

Leave a Reply

Your email address will not be published. Required fields are marked *